- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Fezakinumab is a fully human monoclonal anti-IL22 antibody being investigated for clinical antiinflammatory utility against acute and chronic conditions.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequences identical to those of the heavy and light variable regions of fezakinumab are claimed in patent US7811567, leading to identification of clone 356A11 as fezakinumab .
|Fezakinumab shows cross-species reactivity, blocking IL-22 receptor activation and cellular proliferation induced by murine, monkey and rat IL-22 in addition to the human cytokine .|
|Selectivity at ligand targets|
|Key to terms and symbols||Click column headers to sort|